Top 100 Longevity Charities: The Non-Profit Ground of the Longevity Industry



An open-access special analytical case study by Aging Analytics Agency that delivers an in-depth and thorough review of the current landscape of the global Longevity charity and non-profit sector. By using sophisticated comparative analytical frameworks to assess the activities and impact of Longevity-focused charities, the report is able to perform relevant and tangible benchmarking of the global Longevity non-profit sphere, and to identify the most prospective Longevity charities operating today, in order to provide donors with the necessary tools to make smart donations to charities with a strong chance of making practical progress in the fight against aging.

Top 100 Longevity Charities: The Non-Profit Ground of the Longevity Industry's underlying purpose is to systematize and evaluate the complex ground of the nonprofit counterpart in biomedicine and biotechnology since the rise of the global Longevity Industry in the past several years. These charities are operating at the intersection of cutting edge biotechnology, aging research and advanced biomedicine, and are active at the forefront of some of the most complex and multidimensional fields of science and technology today. As such, any attempt to analyze and benchmark their activities require the use of equally complex and multidimensional analytical methodologies. This report seeks to profile the Top-100 Longevity-focused charities globally, and to identify current trends, challenges and opportunities in the non-profit component of the rapidly-developing Longevity industry.



Supportive, Palliative, Geriatric, Political Organizations



Organizations Concentrated on Basic Research and Direct Application Thereof




Organizations Concentrated on Disruptive Engineering Solutions

The Indispensable Role of the Non-Profit Sector of the Rising Global Longevity Industry

The fight against age-related disease, and the politics of old age and social care in general, have, since the middle of the 20th century, traditionally been associated with the non-profit sector. But in fact the nonprofit sector has been a catalyst for reform at every stage in Longevity's metamorphosis from science to technology, and from technology to an industry. It was disease charities such as Alzheimer's Research UK and American Aging Association, which led the early social and biomedical crusades against familiar diseases of aging, and in so doing became familiar names themselves. And it was biomedical non-profits such as the Buck Institute for Aging and the Max Planck Institute for Biology of Ageing which created and developed the tech sectors which have since come to comprise the current, multi-faceted industry. But more importantly, it was the nonprofit sector which dominated the industry until perhaps only three years ago, and laid the groundwork for its modern commercial activities.

Pharmacoeconomic Dilemma: Profitability and Social Benefit. Hand in Hand

Critical determinants of the thresholds in biotechnological financing are a consequence of the high costs of the prolonged and tedious development processes associated with preclinical and clinical trials. If medicine has not been able to become entirely personalized, preventive and precise, it is because commercial firms have not been able to replace or refine this development paradigm which is the cornerstone of the biomedical for-profit arrangement. So, as a response to missing markets, nonprofit biomedical and biotechnology companies appear as a real opportunity, even for the commercial sector and not only for social benefit in both the developed and developing world. This is particularly valid with respect to P4 Medicine, the correction of age-related diseases and geriatric syndromes, and the global Longevity Industry. Joint participation of both sectors has the potential to fill this gap left in the market because of the understandable needs of the for-profit Longevity market.



Top-100 Longevity Charities. Distribution by Main Field of Research

Biogerontology



Clinical Translation



Social Impact of Aging



Al Technologies within Longevity and Ageing Research





Research of AD and Dementia

